Press release from Acarix AB (publ) 2017-05-24
Acarix will publish the interim report for January – march 2017
Today, Wednesday 24 majl, publish Acarix its interim report for the period January – march 2017 at the company’s website www.acarix.com.
The interim report is also attached in the press release.
The first quarter of 2017 has been a busy time for Acarix in and with the preparation of the commercialisation of CADScor®System. We have progressed with our strategy to gradually increase the level of awareness internationally of the company and we have benefited from the increased interest after listing on Nasdaq First North Premier. “
Summary of CEO SØREN RYSHOLT CHRISTIANSENs comment to the report.
For further information, please contact:
Søren Rysholt Christiansen, CEO E-mail: dksrc@acarix.com Telephone: +45 2777 1112
The information above is such that Acarix AB (publ) is obliged to publish in accordance with the EU market abuse regulation 596/2014. The information was submitted for publication, through the agency of the contact person listed above, at 08:00 on 24 may 2017.
To the editors:
Acarix, CADScor®System and the measurement of heart sounds
Acarix was founded in 2009 and since 2010, the Danish venture capital companies, SEED Capital (DK) and Sunstone Life Science Ventures (DK) funded the development of the company until the listing on the First North Premium, in december 2016. Acarix has also strengthened its management team with new people with experience from senior positions within the international medtech company – the CEO Søren Rysholt Christiansen previously worked at ELOS Medtech, GN ReSound and Cook Medical.
Acarix CADScor®System is based on cutting-edge research in the ljuddetektion and signalprocess. It has long been known that both the heart’s contraction and turbulent blood flow gives rise to sound. Kontraktionsrelaterade sound occurs in the lower frequencies, while the turbulent noises from blood flow caused by partial obstruction (stenosis) in the kransartärerna) causes a sound of higher frequency. The detection of these murmurs require devices with high sensitivity because the energy of the murmur is very weak. To detect and register the murmur arising from the coronary arteries requires not only an advanced sensor, but also that the detector placement on the skin over the heart is such that the recorded signal is optimized and that the external noise is avoided.
CADScor®System with 97% certainty (negative predictive value) exclude kransartärsjukdom, that is to say that the diagnostic accuracy is very high. Acarix believe that this opens the possibility for the method to be used as a first test, which reduces patient anxiety and shorten the waiting time, while improving the prioritisation of patients in need of more expensive and invasive diagnostic methods.
Acarix CADScor®System is built as an all-in-one system comprehensive recording of blåsljuden, signal processing and presentation of p.k. patient-specific CAD-score, on the device’s screen.
CADScor®System also includes the necessary electronics to instruct the staff and guide the patient through the mätperioderna directly on the screen. The system also includes a docking station for the daily test and calibration of the sensor. The system is integrated with an adhesive plate that locks the CADScor®sensor in a fixed position above the heart during the measurement.
The software in the Acarix CADScor®System ensures that the recording is made under controlled conditions.
CADScor®System is CE-certified (by TÜV 2015). Commercial launch is planned in 2017.
See more at www.acarix.com.
Acarix Interim Report Q1 2017
Press release_Acarix AB_Delårsrapport_Kv1
